TSH Biopharm Corporation Limited (TPEX:8432)
Taiwan
· Delayed Price · Currency is TWD 51.00
-1.10 (-2.11%)
Mar 9, 2026, 1:30 PM CST
TSH Biopharm Corporation Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,337 | 1,116 | 810.92 | 741.07 | 413.48 | Upgrade
|
| Revenue Growth (YoY) | 19.79% | 37.59% | 9.43% | 79.22% | -7.68% | Upgrade
|
| Cost of Revenue | 655.79 | 532.95 | 411.02 | 351.2 | 166.13 | Upgrade
|
| Gross Profit | 680.74 | 582.76 | 399.9 | 389.87 | 247.36 | Upgrade
|
| Selling, General & Admin | 436.86 | 384.16 | 313.39 | 289.71 | 168.33 | Upgrade
|
| Research & Development | 24.62 | 27.99 | 24.81 | 31.09 | 23.52 | Upgrade
|
| Other Operating Expenses | 0.9 | - | - | - | - | Upgrade
|
| Operating Expenses | 462.37 | 412.91 | 336.27 | 323.85 | 191.74 | Upgrade
|
| Operating Income | 218.37 | 169.86 | 63.63 | 66.03 | 55.62 | Upgrade
|
| Interest Expense | -0.8 | -0.46 | -0.69 | -0.7 | -0.08 | Upgrade
|
| Interest & Investment Income | 8.27 | 11.98 | 13.06 | 9.71 | 8.46 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.33 | -0.43 | 6.39 | -1.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 8.94 | 1.39 | 0.56 | -0.13 | -1.23 | Upgrade
|
| EBT Excluding Unusual Items | 234.79 | 183.1 | 76.13 | 81.3 | 61.51 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.87 | -0.04 | -0.06 | -0 | Upgrade
|
| Asset Writedown | - | -8.8 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.05 | Upgrade
|
| Pretax Income | 234.79 | 173.43 | 76.09 | 81.24 | 61.55 | Upgrade
|
| Income Tax Expense | 46.97 | 39.29 | 11.11 | 15.1 | 14.44 | Upgrade
|
| Earnings From Continuing Operations | 187.82 | 134.15 | 64.98 | 66.14 | 47.11 | Upgrade
|
| Minority Interest in Earnings | -48.56 | -21.06 | -2.99 | -4.25 | - | Upgrade
|
| Net Income | 139.26 | 113.09 | 61.99 | 61.89 | 47.11 | Upgrade
|
| Net Income to Common | 139.26 | 113.09 | 61.99 | 61.89 | 47.11 | Upgrade
|
| Net Income Growth | 23.14% | 82.44% | 0.16% | 31.38% | -23.49% | Upgrade
|
| Shares Outstanding (Basic) | 38 | 38 | 38 | 38 | 38 | Upgrade
|
| Shares Outstanding (Diluted) | 38 | 38 | 38 | 38 | 38 | Upgrade
|
| Shares Change (YoY) | 0.05% | 0.04% | -0.05% | 0.05% | 0.01% | Upgrade
|
| EPS (Basic) | 3.63 | 2.95 | 1.61 | 1.61 | 1.23 | Upgrade
|
| EPS (Diluted) | 3.62 | 2.94 | 1.61 | 1.61 | 1.23 | Upgrade
|
| EPS Growth | 23.13% | 82.61% | - | 31.23% | -23.32% | Upgrade
|
| Free Cash Flow | 135 | 182.04 | 28.49 | 30.62 | 68.33 | Upgrade
|
| Free Cash Flow Per Share | 3.51 | 4.74 | 0.74 | 0.80 | 1.78 | Upgrade
|
| Dividend Per Share | - | 2.120 | 1.280 | 1.600 | 1.500 | Upgrade
|
| Dividend Growth | - | 65.63% | -20.00% | 6.67% | -16.67% | Upgrade
|
| Gross Margin | 50.93% | 52.23% | 49.31% | 52.61% | 59.82% | Upgrade
|
| Operating Margin | 16.34% | 15.22% | 7.85% | 8.91% | 13.45% | Upgrade
|
| Profit Margin | 10.42% | 10.14% | 7.64% | 8.35% | 11.39% | Upgrade
|
| Free Cash Flow Margin | 10.10% | 16.32% | 3.51% | 4.13% | 16.52% | Upgrade
|
| EBITDA | 245.11 | 185.11 | 77.65 | 79.28 | 60.87 | Upgrade
|
| EBITDA Margin | 18.34% | 16.59% | 9.58% | 10.70% | 14.72% | Upgrade
|
| D&A For EBITDA | 26.74 | 15.26 | 14.02 | 13.25 | 5.26 | Upgrade
|
| EBIT | 218.37 | 169.86 | 63.63 | 66.03 | 55.62 | Upgrade
|
| EBIT Margin | 16.34% | 15.22% | 7.85% | 8.91% | 13.45% | Upgrade
|
| Effective Tax Rate | 20.00% | 22.65% | 14.61% | 18.58% | 23.46% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.